<DOC>
	<DOCNO>NCT02982902</DOCNO>
	<brief_summary>The purpose study determine specific type cell-based immunotherapy , use T-cells donor specific cytomegalovirus ( CMV ) feasible treat infection CMV . Adoptive T-cell therapy investigational ( experimental ) therapy work use blood donor select T-cells respond specific infectious entity . These select T-cells infused patient , try give immune system ability fight infection . Adoptive T-cell therapy experimental approve Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>T Cell Therapy Opportunistic Cytomegalovirus Infection</brief_title>
	<detailed_description>The primary objective study determine feasibility treatment opportunistic cytomegalovirus ( CMV ) infection hematopoietic stem cell transplant ( HSCT ) virus-specific , antigen-selected T-cells , select use CliniMACS prodigy system . Secondary Objective ( ) - To describe safety profile infusion CMV- specific , antigen select T-cells . - To describe toxicity relate infusion CMV- specific , antigen select T-cells . - To describe rate eradication opportunistic CMV infection HSCT treatment CMV-specific , antigen-selected T-cells use CliniMACS Prodigy System . This feasibility study include single treatment cohort .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Opportunistic Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Patients must receive allogeneic hematopoietic stem cell transplant great 30 day posttransplant time registration Patients must document opportunistic CMV infection , reactivation ; criterion include ( follow criterion must meet ) Patients may asymptomatic viremia ( &gt; 1000 copies/ml ) OR presence symptom secondary CMV infection , AND Patients must ONE OF THE NEXT FOUR CRITERIA : Absence improvement viral load ≥ 14 day antiviral therapy ganciclovir , valganciclovir foscarnet ( decrease least 1 log , i.e . 10fold ) New , persistent and/or worsen CMVrelated symptom , sign and/or marker end organ compromise antiviral therapy ganciclovir , valganciclovir foscarnet , Have contraindication experience adverse effect antiviral therapy ganciclovir , valganciclovir foscarnet . Second recurrence CMV viremia , CMVrelated symptom , sign and/or marker end organ compromise . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 3 Women childbearing potential men must agree use adequate contraception ( double barrier method birth control abstinence ) 4 week prior study entry , duration study participation 3 month complete treatment . Subjects must ability understand willingness sign write informed consent document , assent document . Pregnant breastfeed woman exclude study . Patients opportunistic viral infection CMV . Patients active , grade 24 , acute graft vs. host disease ( GVHD ) , chronic GVHD condition require high dos glucocorticosteroid ( &gt; 0.5 mg/kg/day prednisone equivalent ) treatment Treatment antithymocyte globulin within 28 day plan infusion virus specific , antigen select T cell . Treatment virus specific T cell within 6 week ( 42 day ) plan infusion . Donor eligibility Related donor T cell must least partially HLA compatible , matching recipient least 3/6 HLA locus ( HLAA , HLAB , HLADRB1 loci consider ) . Must evidence serologic response ( i.e . seropositive ) CMV . Age ≥ 18 year Must meet criterion donor selection define Standard Operating Procedures University Hospitals Seidman Cancer Center Stem Cell Transplant Program Must capable undergo single standard 2 blood volume leukapheresis donation one unit whole blood</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>T-Cell Therapy</keyword>
	<keyword>Lymphoproliferative Disorder</keyword>
</DOC>